# GIP

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/gip
Canonical HTML page: https://gethealthbrief.com/entity/gip

## Timeline

- **2027-Q1**: Expected FDA submission — Lilly plans to file retatrutide for FDA approval.
- **2026-08-03**: Early access program announced — Lilly announced an expanded access program for retatrutide, allowing eligible patients to receive the drug before FDA approval.
- **2026-07-01**: 80-week trial results released — Lilly reported 22.6% average weight loss with highest retatrutide dose in adults with severe obesity and heart disease.

## Recent coverage (1 stories)

### Eli Lilly’s retatrutide EAP: access for patients with 2+ severe comorbidities
2026-08-05 10:24:43 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Eli Lilly opens an expanded access program for its triple-agonist retatrutide, offering a potential lifeline to patients with refractory obesity and multiple complications who cannot wait for FDA approval. The program highlights ongoing access gaps in obesity care and the need for real-world evidence.
Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-expanded-access-obesity-drug-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.